nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

01.11.2014 | Head and Neck

The association between BRAF ^V600E mutation and pathological features in PTC

verfasst von: Xin Liu, Kangkang Yan, Xuejun Lin, Longyu Zhao, Wenxiu An, Chunpeng Wang, Xiaodong Liu

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

The BRAF ^V600E mutation is a common genetic alteration in papillary thyroid carcinoma (PTC) and is associated with some pathological features. The association has been widely reported, but results were inconclusive. In this study a meta-analysis was done to explore the association between BRAF^V600E mutation and pathological features in papillary thyroid carcinoma. Medline, PubMed and Web of Science were searched. A total of 69 studies that included 14,170 PTC patients were identified. The outcomes were from 2004 to October 2013. STATA12.0 software package was used to analyze the data. The result was assessed based on pooled odds ratios (ORs) with 95 % confidence intervals (CIs). The results showed that the BRAF ^V600E mutation was associated with extra-thyroidal extension (OR = 2.09, 95 % CI = 1.69–2.58), advanced TNM stage (OR = 1.90, 95 % CI = 1.62–2.22), lymph node metastasis (OR = 1.68, 95 % CI = 1.41–2.01), multifocality (OR = 1.22, 95 % CI = 1.06–1.40), and recurrence (OR = 2.50, 95 % CI = 1.73–3.59). The meta-analysis suggested the potential roles of BRAF ^V600E mutation in pathological features. BRAF ^V600E might provide prognostic and diagnostic information for papillary thyroid carcinoma.

Pacini F, Castagna MG (2012) Approach to and treatment of differentiated thyroid carcinoma. Med Clin N Am 96(2):369–383. doi:10.1016/j.mcna.2012.01.002 PubMedCrossRef

Kitano M, Sugitani I, Toda K, Ikenaga M, Motoi N, Yamamoto N, Hotomi M, Fujimoto Y, Kawabata K (2013) Cytopathological review of patients that underwent thyroidectomies based on the diagnosis of papillary thyroid carcinoma by fine needle aspiration cytology but were later found to have benign tumors by histopathology. Surg Today 43(6):632–637. doi:10.1007/s00595-012-0362-y PubMedCrossRef

Hughes DT, Doherty GM (2011) Central neck dissection for papillary thyroid cancer. Cancer Control J Moffitt Cancer Center 18(2):83–88

Caronia LM, Phay JE, Shah MH (2011) Role of BRAF in thyroid oncogenesis. Clin Cancer Res Off J Am Assoc Cancer Res 17(24):7511–7517. doi:10.1158/1078-0432.CCR-11-1155 CrossRef

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D’Cruz A, Rajan MG (2012) BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr pathol 23(2):83–93. doi:10.1007/s12022-011-9184-5 PubMedCrossRef

Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK (2009) Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 94(12):5001–5009. doi:10.1210/jc.2009-1349 PubMedCrossRef

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1,060 cases. J Clin Endocr Metab 95(9):4197–4205. doi:10.1210/Jc.2010-0337 PubMedCrossRef

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo DH, Youn YK (2012) BRAF(V600E) Mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36(2):310–317. doi:10.1007/s00268-011-1383-1 PubMedCrossRef

Zheng XQ, Xia TT, Lin L, Gao SY, Lee YG, Yu Y, Wei SF, Gao M (2012) BRAF(V600E) status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol 10. doi:10.1186/1477-7819-10-104

10.

Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS (2012) Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 203(4):436–441. doi:10.1016/j.amjsurg.2011.02.013 PubMedCrossRef

11.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocr Metab 93(10):3943–3949. doi:10.1210/Jc.2008-0607 PubMedCrossRef

12.

Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M (2012) A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97(7):2333–2340. doi:10.1210/jc.2011-3106 PubMedCrossRef

13.

Pyo JS, Kang G, Kim DH, Chae SW, Park C, Kim K, Do SI, Lee HJ, Kim JH, Sohn JH (2013) Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma. Pathol Res Pract 209(4):228–232. doi:10.1016/j.prp.2013.02.004 PubMedCrossRef

14.

Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, do Park J, Cho BY (2006) Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107(8):1831–1838. doi:10.1002/cncr.22218 PubMedCrossRef

15.

Howell GM, Carty SE, Armstrong MJ, LeBeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L (2011) Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 18(13):3566–3571. doi:10.1245/s10434-011-1781-5 PubMedCrossRef

16.

Pelttari H, Schalin-Jantti C, Arola J, Loyttyniemi E, Knuutila S, Valimaki MJ (2012) BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. Apmis 120(5):380–386. doi:10.1111/j.1600-0463.2011.02844.x PubMedCrossRef

17.

Moon WJ, Choi N, Choi JW, Kim SK, Hwang TS (2012) BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles. AJR Am J Roentgenol 198(3):668–674. doi:10.2214/AJR.11.7185 PubMedCrossRef

18.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97PubMedCrossRef

19.

Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C (2011) BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer 18(6):669–685. doi:10.1530/ERC-11-0076 PubMedCrossRef

20.

Patel A, Klubo-Gwiezdzinska J, Hoperia V, Larin A, Jensen K, Bauer A, Vasko V (2011) BRAF(V600E) mutation analysis from May-Grunwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma. Endocr Pathol 22(4):195–199. doi:10.1007/s12022-011-9180-9 PubMedCrossRef

21.

O’Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS (2010) BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148(6):1139–1145. doi:10.1016/j.surg.2010.09.005 PubMedCrossRef

22.

Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY (2012) BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 39(2):198–203. doi:10.1016/j.anl.2011.07.011 PubMedCrossRef

23.

Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, Oh MH, Yang SH, Kim CJ (2013) BRAF(V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol 20(3):759–766. doi:10.1245/s10434-012-2494-0 PubMedCrossRef

24.

Lee JI, Jang HW, Kim SW, Kim JW, Oh YL, Chung JH (2013) BRAF(V600E) mutation in fine-needle aspiration aspirates: association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck J Sci Spec 35(4):548–553. doi:10.1002/Hed.22997 CrossRef

25.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V (2010) BRAF(V600E) mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer. Mod Pathol Off J US Can Acad Pathol Inc 23(8):1052–1060. doi:10.1038/modpathol.2010.86

26.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydin O, Altiok E, Giray S, Azizlerli H (2012) BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2):404–410. doi:10.1007/s12020-012-9651-x PubMedCrossRef

27.

Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML (2013) BRAF(V600E) mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 26(1):62–70. doi:10.1038/modpathol.2012.152 PubMedCrossRef

28.

Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH (2012) Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4,585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocr Metab 97(7):2299–2306. doi:10.1210/Jc.2011-3135 PubMedCrossRef

29.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R (2006) Correlation between B-RAF(V600E) mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13(2):455–464. doi:10.1677/Erc.1.01086 PubMedCrossRef

30.

Jeong D, Jeong Y, Lee S, Lee H, Lee W, Kim H, Park D, Park S, Mu W, Cho HD, Oh MH, Lee SS, Yang SH, Kim CJ (2012) Detection of BRAF(V600E) mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR: a comparison with direct sequencing. Korean J Pathol 46(1):61–67. doi:10.4132/KoreanJPathol.46.1.61 PubMedCrossRefPubMedCentral

31.

Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M (2006) Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154(2):341–348. doi:10.1530/eje.1.02072 PubMedCrossRef

32.

Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, Shong M, Jo YS (2012) Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol 167(1):93–101. doi:10.1530/Eje-12-0010 PubMedCrossRef

33.

Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36(6):844–850. doi:10.1097/PAS.0b013e318246b527 PubMedCrossRef

34.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D’Armiento M (2012) In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 77(5):780–786. doi:10.1111/j.1365-2265.2012.04465.x CrossRef

35.

Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA (2012) Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152(6):977–983. doi:10.1016/j.surg.2012.08.019 PubMedCrossRefPubMedCentral

36.

Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K (2007) Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57(1):12–20. doi:10.1111/j.1440-1827.2007.02050.x PubMedCrossRef

37.

Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW (2009) Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of mirnas in papillary thyroid carcinoma. Horm Metab Res 41(6):482–487. doi:10.1055/s-0029-1215558 PubMedCrossRef

38.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S (2011) Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J 58(5):381–393PubMedCrossRef

39.

Park HS, Jung CK, Lee SH, Chae BJ, Lim DJ, Park WC, Song BJ, Kim JS, Jung SS, Bae JS (2012) Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer. Cancer Sci 103(2):305. doi:10.1111/j.1349-7006.2011.02161.x

40.

Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML (2012) Papillary thyroid carcinomas with and without BRAF? V600E mutations are morphologically distinct. Histopathology 60(7):1052–1059. doi:10.1111/j.1365-2559.2011.04149.x PubMedCrossRef

41.

Hwang J, Shin JH, Han BK, Ko EY, Kang SS, Kim JW, Chung JH (2010) Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction. AJR Am J Roentgenol 194(5):W425–W430. doi:10.2214/AJR.09.3512 PubMedCrossRef

42.

Wang W, Zhao W, Wang H, Teng X, Chen X, Li Z, Yu X, Fahey TJ 3rd, Teng L (2012) Poorer prognosis and higher prevalence of BRAF(V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 19(1):31–36. doi:10.1245/s10434-011-2096-2 PubMedCrossRef

43.

Zheng XQ, Wang C, Xu M, Yu Y, Yun XW, Jia YS, Wei SF, Ren XB, Gao M (2012) Progression of solitary and multifocal papillary thyroid carcinoma—a retrospective study of 368 patients. Chin Med J 125(24):4434–4439PubMed

44.

Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS (2011) Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96(3):658–664. doi:10.1210/jc.2010-1082 PubMedCrossRef

45.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65(3):364–368. doi:10.1111/j.1365-2265.2006.02605.x CrossRef

46.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK (2005) The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 63(5):588–593. doi:10.1111/j.1365-2265.2005.02389.x CrossRef

47.

Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY (2010) Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23(9):1201–1208. doi:10.1038/modpathol.2010.116 PubMedCrossRef

48.

Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN (2013) Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. doi:10.1016/j.surg.2013.06.020 PubMed

49.

Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AKY (2011) Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 42(4):500–506. doi:10.1016/j.humpath.2009.09.023 PubMedCrossRef

50.

Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A (2013) BRAF mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg. doi:10.1007/s00268-013-2223-2 PubMed

51.

Moon HJ, Kwak JY, Kim EK, Choi JR, Hong SW, Kim MJ, Son EJ (2009) The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol 16(11):3125–3131. doi:10.1245/s10434-009-0644-9 PubMedCrossRef

52.

Kang SY, Ahn S, Lee SM, Jeong JY, Sung JY, Oh YL, Kim KM (2013) Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. Diagn Pathol 8(1):121. doi:10.1186/1746-1596-8-121 PubMedCrossRefPubMedCentral

53.

Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T (2007) Clinical significance of BRAF(V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27(5B):3645–3649PubMed

54.

Kang G, Cho EY, Shin JH, Chung JH, Kim JW, Oh YL (2012) Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. Cancer Cytopathol 120(1):44–51. doi:10.1002/cncy.20179 PubMedCrossRef

55.

Yim JH, Kim ES, Choi HJ, Jeon MJ, Han JM, Kim WG, Kim TY, Gong G, Kim SY, Kim WB, Shong YK (2012) Association between STAT1 activity and BRAF mutations in papillary thyroid carcinomas. J Surg Oncol 106(6):719–723. doi:10.1002/jso.23125 PubMedCrossRef

56.

Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, Teng W, Xing M (2008) Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 113(2):247–255. doi:10.1002/cncr.23548 PubMedCrossRef

57.

Oler G, Cerutti JM (2009) High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115(5):972–980. doi:10.1002/cncr.24118 PubMedCrossRef

58.

Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B (2010) BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 33(5):318–324. doi:10.3275/6722 PubMedCrossRef

59.

Kleiman DA, Buitrago D, Crowley MJ, Beninato T, Veach AJ, Zanzonico PB, Jin M, III TJF, Zarnegar R (2013) TSH increases iodine uptake by thyroid cancer cells during BRAF silencing. J Surg Res 182(1):85–93PubMedCrossRefPubMedCentral

60.

Xing MZ, Clark D, Guan HX, Ji MJ, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.1200/Jco.2008.20.1426 PubMedCrossRefPubMedCentral

61.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R (2008) BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15(1):191–205. doi:10.1677/Erc-07-0212 PubMedCrossRef

62.

Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398. doi:10.1210/jc.2012-1775 PubMedCrossRef

63.

Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ (2009) BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid 19(4):347–354. doi:10.1089/thy.2008.0246 PubMedCrossRef

64.

Kang SH, Pyo JY, Yang SW, Hong SW (2013) Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. Am J Clin Pathol 139(6):759–764. doi:10.1309/AJCPN3ULH6YWBHPH PubMedCrossRef

65.

Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, Fiorentino M (2013) Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol-Head Neck Surg Off J Am AcaD Otolaryngol-Head Neck Surg 148 (6):919–925. doi:10.1177/0194599813481942

66.

Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M, Koo BS (2012) Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 97(11):3996–4003. doi:10.1210/jc.2012-2444 PubMedCrossRef

67.

Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F (2007) Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92(11):4085–4090. doi:10.1210/jc.2007-1179 PubMedCrossRef

68.

Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M (2008) BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28(1A):305–308PubMed

69.

Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻ targeting to the membrane. Endocr Relat Cancer 13(1):257–269. doi:10.1677/erc.1.01119 PubMedCrossRef

70.

Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M (2009) Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94(5):1612–1617. doi:10.1210/jc.2008-2390 PubMedCrossRef

71.

Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M (2006) Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91(9):3667–3670. doi:10.1210/jc.2005-2836 PubMedCrossRef

72.

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P (2004) BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 61(2):239–243. doi:10.1111/j.1365-2265.2004.02089.x CrossRef

73.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT (2005) No correlation between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol 63(4):461–466. doi:10.1111/j.1365-2265.2005.02367.x CrossRef

74.

Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S (2007) Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 120(1):196–200. doi:10.1002/ijc.22290 PubMedCrossRef

75.

Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, do Park J (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7):1764–1773. doi:10.1002/cncr.26500 PubMedCrossRef

76.

Eloy C, Santos J, Soares P, Sobrinho-Simoes M (2011) Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Arch 459(6):595–605. doi:10.1007/s00428-011-1161-3 PubMedCrossRef

77.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G (2008) BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol 68(4):618–634. doi:10.1111/j.1365-2265.2007.03077.x CrossRef

Titel: The association between BRAF V600E mutation and pathological features in PTC
verfasst von: Xin Liu
Kangkang Yan
Xuejun Lin
Longyu Zhao
Wenxiu An
Chunpeng Wang
Xiaodong Liu
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 11/2014
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-013-2872-7

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

The association between BRAF ^V600E mutation and pathological features in PTC

Abstract

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Day surgery for vocal fold lesions using a double-bent 60-mm Cathelin needle

When is radiation therapy in head and neck squamous cell carcinoma not indicated?

Detection of bacterial biofilms in different types of chronic otitis media

The presence of fungal-specific IgE in serum and sinonasal tissue among patients with sinonasal polyposis

Histopathological changes in nasal mucosa with nasal septum deviation

Objective and subjective outcome in 42 patients after treatment of sialolithiasis by transoral incision of Warthon’s duct: a retrospective middle-term follow-up study

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO